UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2007
OR
TRANSITION REPORT
PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition
period from________to_______
COMMISSION FILE
NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235
East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip
code)
(212) 573-2323
(Registrant's telephone number)
Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days.
YES X NO
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, or a non-accelerated filer. See
definition of "accelerated filer and large accelerated filer" in
Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer X
Accelerated filer Non-accelerated
filer
Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act).
YES NO X
At October 31, 2007, 6,829,805,073 shares of the
issuer's voting common stock were outstanding.
FORM 10-Q
For the Quarter
Ended
September 30, 2007
Table
of Contents
PART I. FINANCIAL
INFORMATION
Page
Item 1.
Financial Statements
Condensed
Consolidated Statements of Income for the three months and nine months ended September
30, 2007, and October 1, 2006
Condensed Consolidated
Balance Sheets as of September 30, 2007, and December 31, 2006
Condensed
Consolidated Statements of Cash Flows for the nine months ended September 30,
2007, and October 1, 2006
Notes to
Condensed Consolidated Financial Statements
Review Report
of Independent Registered Public Accounting Firm
20
Item 2.
Management's
Discussion and Analysis of Financial Condition and Results of Operations
21
Item 3.
Quantitative
and Qualitative Disclosures About Market Risk
52
Item 4.
Controls and
Procedures
52
PART II. OTHER
INFORMATION
Item 1.
Legal
Proceedings
52
Item 1A.
Risk Factors
56
Item 2.
Unregistered
Sales of Equity Securities and Use of Proceeds
57
Item 3.
Defaults Upon
Senior Securities
57
Item 4.
Submission of
Matters to a Vote of Security Holders
57
Item 5.
Other
Information
57
Item 6.
Exhibits
58
Signature
59
PART
I - FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three
Months Ended
Nine
Months Ended
(millions, except per common share
data)
Sept. 30,
2007
Oct. 1,
2006
Sept. 30,
2007
Oct. 1,
2006
Revenues
11,990
12,280
35,548
35,768
Costs and expenses:
Cost of sales(a)
4,618
1,962
8,614
5,423
Selling,
informational and administrative expenses(a)
3,768
3,751
10,973
11,027
Research and
development expenses(a)
1,999
1,902
5,829
5,187
Amortization of
intangible assets
774
798
2,372
2,446
Acquisition-related
in-process research and development charges
--
--
283
513
Restructuring
charges and acquisition-related costs
455
249
2,318
816
Other
(income)/deductions - net
(260)
(343)
(1,149)
(958)
Income from
continuing operations before (benefit)/provision for taxes on income and
minority interests
636
3,961
6,308
11,314
(Benefit)/provision
for taxes on income
(161)
717
800
1,769
Minority
interests
10
Income from
continuing operations
796
3,239
5,502
9,535
Discontinued
operations:
Income from
discontinued operations - net of tax
--
120
--
330
Gains/(losses)
on sales of discontinued operations - net of tax
(35)
(82)
23
Discontinued
operations - net of tax
(35)
123
(82)
353
Net income
761
3,362
5,420
9,888
Earnings per common share - basic:
Income from
continuing operations
0.12
0.45
0.79
1.31
Discontinued
operations - net of tax
(0.01)
0.02
(0.01)
0.05
Net income
0.11
0.47
0.78
1.36
Earnings per common share -
diluted:
Income from
continuing operations
0.12
0.44
0.79
1.30
Discontinued
operations - net of tax
(0.01)
0.02
(0.01)
0.05
Net income
0.11
0.46
0.78
1.35
Weighted-average
shares used to calculate earnings per common share:
Basic
6,875
7,228
6,964
7,275
Diluted
6,894
7,251
6,986
7,306
Cash dividends paid per common
share
0.29
0.24
0.87
0.72
(a)
Exclusive of amortization of
intangible assets, except as disclosed in Note 11B. Goodwill and
Other Intangible Assets: Other Intangible Assets.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(millions
of dollars)
Sept. 30,
2007*
Dec. 31,
2006**
ASSETS
Cash and cash equivalents
2,611
1,827
Short-term investments
19,687
25,886
Accounts receivable, less allowance
for doubtful accounts
9,942
9,392
Short-term loans
526
514
Inventories
5,210
6,111
Prepaid expenses and taxes
3,749
3,157
Assets held for sale
115
62
Total current assets
41,840
46,949
Long-term
investments and loans
4,922
3,892
Property, plant and equipment, less
accumulated depreciation
15,714
16,632
Goodwill
21,210
20,876
Identifiable
intangible assets, less accumulated amortization
20,998
24,350
Other assets,
deferred taxes and deferred charges
4,346
2,138
Total assets
109,030
114,837
LIABILITIES
AND SHAREHOLDERS' EQUITY
Short-term borrowings, including
current portion of long-term debt
2,645
2,434
Accounts payable
2,298
2,019
Dividends payable
2,055
Income taxes payable
266
6,466
Accrued compensation and related
items
1,628
1,903
Other current liabilities
7,489
6,510
Liabilities held for sale
--
Total current liabilities
14,328
21,389
Long-term debt
6,041
5,546
Pension benefit
obligations
3,319
3,632
Postretirement
benefit obligations
1,957
1,970
Deferred taxes
7,544
8,015
Other taxes
payable
5,816
--
Other
noncurrent liabilities
3,415
2,927
Total liabilities
42,420
43,479
Shareholders' equity
Preferred stock
103
141
Common stock
442
441
Additional
paid-in capital
69,832
69,104
Employee
benefit trust, at fair value
(577)
(788)
Treasury stock
(54,346)
(46,740)
Retained
earnings
51,063
49,669
Accumulated
other comprehensive income/(expense)
93
(469)
Total shareholders' equity
66,610
71,358
Total liabilities and shareholders'
equity
109,030
114,837
* Unaudited.
** Condensed from audited
financial statements.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Nine
Months Ended
(millions of dollars)
Sept. 30,
2007
Oct. 1,
2006
Operating
Activities:
Net income
5,420
9,888
Adjustments to
reconcile net income to net cash provided by operating activities:
Depreciation
and amortization
4,084
4,026
Share-based
compensation expense
335
506
Acquisition-related
in-process research and development charges
283
513
Asset write-offs
associated with exiting Exubera
2,220
--
Gains on
disposal of investments, products and product lines
(89)
(201)
(Gains)/losses
on sales of discontinued operations
139
(37)
Deferred taxes
from continuing operations
(1,969)
(1,333)
Other deferred
taxes
--
67
Other non-cash
adjustments
343
180
Changes in
assets and liabilities (net of businesses acquired and divested)
(1,180)
(491)
Net cash provided by operating
activities
9,586
13,118
Investing Activities:
Purchases of
property, plant and equipment
(1,218)
(1,438)
Purchases of
short-term investments
(16,606)
(8,472)
Proceeds from
redemptions of short-term investments
23,426
17,346
Purchases of
long-term investments
(1,406)
(835)
Proceeds from redemptions
of long-term investments
173
229
Purchases of
other assets
(93)
(118)
Proceeds from
sales of other assets
29
Proceeds from
the sales of businesses, products and product lines
21
22
Acquisitions,
net of cash acquired
(464)
(1,989)
Other investing
activities
(268)
(82)
Net cash provided by investing
activities
3,594
4,666
Financing Activities:
Increase in
short-term borrowings, net
130
993
Principal
payments on short-term borrowings
(744)
(11,721)
Proceeds from
issuances of long-term debt
1,243
1,051
Principal
payments on long-term debt
(61)
(55)
Purchases of
common stock
(7,494)
(4,496)
Cash dividends
paid
(6,021)
(5,211)
Stock option
transactions and other
537
593
Net cash used
in financing activities
(12,410)
(18,846)
Effect of
exchange-rate changes on cash and cash equivalents
14
(8)
Net increase/(decrease)
in cash and cash equivalents
784
(1,070)
Cash and cash
equivalents at beginning of period
1,827
2,247
Cash and cash
equivalents at end of period
2,611
1,177
Supplemental
Cash Flow Information:
Cash paid
during the period for:
Income taxes
4,207
2,031
Interest
465
579
See
accompanying Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of
Presentation
We prepared the condensed
consolidated financial statements following the requirements of the Securities
and Exchange Commission (SEC) for interim reporting. As permitted under those
rules, certain footnotes or other financial information that are normally
required by accounting principles generally accepted in the United States of
America (GAAP) can be condensed or omitted. Balance sheet amounts and operating
results for subsidiaries operating outside the U.S. are as of and for the
three-month and nine-month periods ended August 26, 2007, and August 27, 2006.
We made certain minor
reclassifications to prior period amounts to conform to the third-quarter 2007
presentation.
Revenues, expenses, assets and
liabilities can vary during each quarter of the year. Therefore, the results
and trends in these interim financial statements may not be representative of
those for the full year.
We are responsible for the unaudited
financial statements included in this document. The financial statements
include all normal and recurring adjustments that are considered necessary for
the fair presentation of our financial position and operating results.
The information included in this
Quarterly Report on Form 10-Q should be read in conjunction with the
consolidated financial statements and accompanying notes included in Pfizer's
Annual Report on Form 10-K for the year ended December 31, 2006.
Note 2. Asset Impairment Charges
and Other Costs Associated with Exiting Exubera
In the third quarter of 2007, after
an assessment of the financial performance of Exubera, an inhalable form of
insulin for the treatment of diabetes, as well as its lack of acceptance by
patients, physicians and payers, we decided to exit the product and recorded
charges totaling $2.8 billion ($2.1 billion net of tax).
Total pre-tax charges for the three
months and nine months ended September 30, 2007, as well as the income statement
line items in which the various charges are recorded, are as follows:
(millions
of dollars)
Customer
Returns -
Revenues
Cost
of
Sales
Selling
Informational &
Administrative
Expenses
Research
Development
Total
Intangible
asset impairment charges
--
1,064
41
--
1,105
Inventory
write-offs
--
661
--
--
661
Fixed assets
impairment charges
--
451
--
454
Other exit
costs(a)
10
404
42
128
584
Total
10
2,580
83
131
2,804
(a)
On
the balance sheet primarily included in Other current liabilities.
The asset write-offs of
$2.2 billion (intangibles, inventory and fixed assets) represent non-cash
charges. The other exit costs, primarily contract and other termination costs, among
other liabilities, will result in future cash expenditures and are associated
with marketing and research programs, as well as manufacturing operations
related to Exubera. We expect that substantially all of the cash spending will
occur within the next year. During the implementation of the exit strategy,
certain additional cash costs will be incurred and reported in future periods,
such as maintenance-level operating costs. However, those future costs are not
expected to be significant. We expect that substantially all exit activities
will be completed within the next year.
Note 3. Adoption of New
Accounting Policy
As of January 1, 2007, we adopted the provisions of Financial Accounting
Standards Board (FASB) Interpretation No. 48 (FIN 48), Accounting for
Uncertainty in Income Taxes, an interpretation of SFAS 109, Accounting for
Income Taxes, and supplemented by FASB Financial Staff Position FIN
48-1, Definition of Settlement in FASB Interpretation No. 48, issued May
2, 2007, and changed our policy related to the accounting for income tax
contingencies. To understand the cumulative effect of these accounting changes,
see Note 7A. Taxes on Income: Adoption of New Accounting
Standard.
We continue to account for income tax
contingencies using a benefit recognition model. Beginning January
1, 2007, if we consider that a tax position is 'more likely than not' of being
sustained upon audit, based solely on the technical merits of the position, we
recognize the benefit. We measure the benefit by determining the amount that is
greater than 50% likely of being realized upon settlement, presuming that the
tax position is examined by the appropriate taxing authority that has full
knowledge of all relevant information. These assessments can be complex and we
often obtain assistance from external advisors.
Under the benefit recognition model, if our initial assessment
fails to result in the recognition of a tax benefit, we regularly monitor our
position and subsequently recognize the tax benefit: (i) if there are changes
in tax law or analogous case law that sufficiently raise the likelihood of
prevailing on the technical merits of the position to more likely than not;
(ii) if the statute of limitations expires; or (iii) if there is a completion
of an audit resulting in a favorable settlement of that tax year with the
appropriate agency. We regularly reevaluate our tax positions based on the
results of audits of federal, state and foreign income tax filings, statute of
limitations expirations, and changes in tax law that would either increase or
decrease the technical merits of a position relative to the more likely than
not standard.
Liabilities associated with uncertain tax positions are now classified as
current only when we expect to pay cash within the next 12 months. Interest and
penalties, if any, continue to be recorded in (Benefit)/provision for taxes
on income and are classified on the balance sheet with the related tax
liability.
Prior to 2007, our policy had been to account for income tax
contingencies based on whether we determined our tax position to be 'probable'
under current tax law of being sustained, as well as an analysis of potential
outcomes under a given set of facts and circumstances. In addition, we
previously considered all tax liabilities as current once the associated tax
year was under audit.
Note 4. Acquisitions
In the first quarter of 2007, we
acquired BioRexis Pharmaceutical Corp., a privately held biopharmaceutical
company with a number of diabetes candidates and a novel technology platform
for developing new protein drug candidates, and Embrex, Inc., an animal health
company that possesses a unique vaccine delivery system known as Inovoject that
improves consistency and reliability by inoculating chicks while they are still
in the egg. In connection with these and other smaller acquisitions, we
recorded $283 million in Acquisition-related in-process research and
development charges in the first quarter of 2007.
In the second quarter of 2006, we completed the acquisition of all the
outstanding shares of Rinat Neuroscience Corp., a biologics company with
several new central-nervous-system product candidates. In connection with this
and other smaller acquisitions, we recorded $513 million in Acquisition-related
in-process research and development charges in the second quarter of 2006.
On February 28, 2006, we completed
the acquisition of the sanofi-aventis worldwide rights, including patent rights
and production technology, to manufacture and sell Exubera, an inhaled form of
insulin and the insulin-production business and facilities located in
Frankfurt, Germany, previously jointly owned by Pfizer and sanofi-aventis, for
approximately $1.4 billion (including transaction costs). All assets recorded
in connection with this acquisition (other than the $166 million allocated to
Pharmaceutical goodwill) have now been written off. See Note 2. Asset
Impairment Charges and Other Costs Associated with Exiting Exubera. Prior
to the acquisition, in connection with our collaboration agreement with
sanofi-aventis, we recorded a research and development milestone due to us from
sanofi-aventis of $118 million ($71 million, after tax) in the first
quarter of 2006 in Research and development expenses upon the approval
of Exubera in January 2006 by the Food and Drug Administration (FDA).
Note 5. Discontinued
Operations
The following amounts, primarily related
to our Consumer Healthcare business which was sold in December 2006 for $16.6 billion,
have been segregated from continuing operations and included in Discontinued
operations - net of tax in the condensed consolidated statements of income:
Three
Months Ended
Nine
Months Ended
(millions
of dollars)
Sept. 30,
2007
Oct. 1,
2006
Sept. 30,
2007
Oct. 1,
2006
Revenues
--
974
--
2,920